Darunavir Ethanolate CAS 635728-49-3 Purity ≥99.0% API Factory Anti-HIV HIV Protease Inhibitor
Manufacturer Supply Darunavir Related Products:
Darunavir CAS 206361-99-1
Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Chemical Name | Darunavir Ethanolate |
| Synonyms | DRV; Prezista; TMC114 Ethanolate; UNII-33O78XF0BW; N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester compd. with ethanol |
| CAS Number | 635728-49-3 |
| CAT Number | RF-API69 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C29H43N3O8S |
| Molecular Weight | 593.73 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Off-White Crystalline Powder |
| Identification IR | Corresponds to the Standard Spectrum |
| Specific Rotation | -0.5°~ +0.5° |
| Related Substances | (by HPLC) |
| Max Single Impurity | ≤0.20% |
| Total Impurities | ≤0.50% |
| Water (K.F) | ≤1.0% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤10ppm |
| Content of Ethanol | ≤7.5% (GC) |
| Residual Solvents | Methanol ≤0.30% |
| Purity | ≥99.0% (HPLC) |
| Test Standard | Enterprise Standard |
| Usage | Darunavir Ethanolate HIV-1 Protease Inhibitor Anti-HIV Antiviral |
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. Derivative of Darunavir, a second generation HIV-1-protease inhibitor; structurally similar to amprenavir. Antiviral. It is a COVID19-related research product. Unfortunately, DRV has low solubility in water and poor bioavailability, therefore it requires administration in relatively high doses in order to exhibit therapeutic efficacy. Darunavir is a broad-spectrum potent inhibitor active against HIV-1 clinical isolates with minimal cytotoxicity. Darunavir forms hydrogen bonds with the conserved main-chain atoms of Asp29 and Asp30 of the protease. These interactions are proposed to be critical for the potency of this compound against HIV isolates that are resistant to multiple protease inhibitors. In an in vitro study in MT-2 cells, the potency of darunavir is greater than that of saquinavir, amprenavir, nelfinavir, indinavir, lopinavir and ritonavir. Darunavir is primarily metabolized by the hepatic cytochrome P450 (CYP) enzymes, primarily CYP3A. The ‘boosting’ dose of ritonavir acts an an inhibitor of CYP3A, thereby increasing darunavir bioavailability. Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutati.
